INNV Stock Forecast & Price Target

InnovAge Holding is attractive because FY27 guidance points to EBITDA of $105M-$115M, revenue of $1,050M-$1,085M, and census of 8,625-8,850, all above Street expectations while still using prudent assumptions. Its FY4Q26 results showed strong operating leverage, with EBITDA of $24.3M up 114% year over year, revenue of $262.0M up 18%, and medical cost growth of just 0.3%, reflecting lower SNF utilization and better pharmacy trends. The outlook is further supported by disciplined margin management, ongoing investments in member experience and AI, and a post-turnaround business that management believes can sustain 10%+ EBITDA margins as PACE growth and payor optimization improve.

InnovAge Holding is challenged by heavy regulatory dependence on Medicare and Medicaid, where sanctions on new member enrollment and potential funding pressure from state budgets could directly impair growth and margins. Its exposure is heightened by the v28 risk-adjustment transition, which may create reimbursement headwinds even if dementia coding offers some offset, while management also flagged the difficulty of sustaining profitability in at-risk contracts. Although the PACE model has transparent value delivery and the company’s 20 centers plus December 2023 acquisitions offer some consolidation upside, the negative outlook reflects that policy, reimbursement, and margin risks remain the dominant fundamental threats.